BR0215193A - Formulações de azitromicina diretamente compressìveis - Google Patents

Formulações de azitromicina diretamente compressìveis

Info

Publication number
BR0215193A
BR0215193A BR0215193-6A BR0215193A BR0215193A BR 0215193 A BR0215193 A BR 0215193A BR 0215193 A BR0215193 A BR 0215193A BR 0215193 A BR0215193 A BR 0215193A
Authority
BR
Brazil
Prior art keywords
azithromycin
tablet
mga
pharmaceutically acceptable
acceptable excipient
Prior art date
Application number
BR0215193-6A
Other languages
English (en)
Inventor
Brendn John Murphy
Steven William Collier
Ernest Shing Quan
Barbara Alice Johnson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0215193A publication Critical patent/BR0215193A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES DE AZITROMICINA DIRETAMENTE COMPRESSìVEIS". A presente invenção refere-se a uma mistura seca, usada para formar comprimidos de azitromicina por compressão direta, compreendendo azitromicina não-diidrato e pelo menos um excipiente farmaceuticamente aceitável. Esta invenção refere-se também a um comprimido de azitromicina compreendendo azitromicina não-diidratada e pelo menos um excipiente farmaceuticamente aceitável. Preferencialmente, o comprimido de azitromicina é formado por compressão direta da mistura seca, da presente invenção, para formar o referido comprimido de azitromicina. Preferencialmente, o comprimido de azitromicina, da presente invenção, contém uma dosagem de 250 mgA, 500 mgA e 600 mgA. Esta invenção refere-se ainda a um comprimido de azitromicina que é produzido formando uma mistura seca de uma azitromicina não granulada de forma A e pelo menos um excipiente farmaceuticamente aceitável. O comprimido de azitromicina é então formado por compressão direta da mistura seca.
BR0215193-6A 2001-12-21 2002-12-09 Formulações de azitromicina diretamente compressìveis BR0215193A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34348001P 2001-12-21 2001-12-21
PCT/IB2002/005222 WO2003053416A1 (en) 2001-12-21 2002-12-09 Directly compressible formulations of azithromycin

Publications (1)

Publication Number Publication Date
BR0215193A true BR0215193A (pt) 2004-11-16

Family

ID=23346277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215193-6A BR0215193A (pt) 2001-12-21 2002-12-09 Formulações de azitromicina diretamente compressìveis

Country Status (20)

Country Link
US (4) US20030165563A1 (pt)
EP (1) EP1455758A1 (pt)
JP (1) JP2005513099A (pt)
KR (1) KR100632339B1 (pt)
CN (1) CN1668282A (pt)
AR (1) AR037930A1 (pt)
AU (1) AU2002348884A1 (pt)
BR (1) BR0215193A (pt)
CA (1) CA2469246A1 (pt)
IL (1) IL161996A0 (pt)
MX (1) MXPA04005105A (pt)
NO (1) NO20043110L (pt)
NZ (1) NZ532707A (pt)
PA (1) PA8562201A1 (pt)
PE (1) PE20030591A1 (pt)
PL (1) PL371259A1 (pt)
RU (1) RU2277914C2 (pt)
TW (1) TW200301138A (pt)
WO (1) WO2003053416A1 (pt)
ZA (1) ZA200403486B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
EP1455758A1 (en) * 2001-12-21 2004-09-15 Pfizer Products Inc. Directly compressible formulations of azithromycin
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0211620D0 (en) * 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
EP1648472A2 (en) * 2003-07-01 2006-04-26 Ranbaxy Laboratories, Ltd. Stable oral compositions of azithromycin monohydrate
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
JP2007513146A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 液体系プロセスによるアジスロマイシンマルチパーティキュレート剤形
BRPI0417360A (pt) 2003-12-04 2007-03-13 Pfizer Prod Inc método para a preparação de multiparticulados farmacêuticos
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
EP1691786A1 (en) 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
EP1830860A2 (en) * 2004-12-21 2007-09-12 Pfizer Products Incorporated Stable non-dihydrate azithromycin oral suspensions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含***并[4,5-d]嘧啶衍生物之組合物
US20080045548A1 (en) * 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
EP2561877A1 (en) * 2006-12-20 2013-02-27 Mylan Pharmaceuticals ULC A Composition containing a Bisphosphonic Acid in combination with Vitamin D
ES2686081T3 (es) * 2007-07-31 2018-10-16 Cargill, Incorporated Dextrosa comprimible directamente
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
HUE028690T2 (en) * 2008-03-18 2016-12-28 Dikovskiy Aleksander Vladimirovich Antibiotic and prebiotic pharmaceutical composition for antibacterial therapy to prevent and treat dysbiosis
CN101998859B (zh) * 2008-03-18 2014-03-05 亚历山大·弗拉基米罗维奇·季科夫斯基 用于预防与抗生素肠道给药相关的生态失调的药物组合物
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
US20150242974A1 (en) 2014-02-24 2015-08-27 Mindojo Ltd. Adaptive e-learning engine with embedded datagraph structure
US20160145548A1 (en) * 2014-11-20 2016-05-26 The Procter & Gamble Company Cleaning composition refill for an automatic dishwasher dispensing device
CN105193753A (zh) * 2015-10-30 2015-12-30 成都通德药业有限公司 一种阿奇霉素分散片的制备方法
CN110633487B (zh) * 2019-07-03 2023-03-14 北京中医药大学 直接压片的片剂处方的设计方法
CN111467362B (zh) * 2020-05-09 2021-07-06 北京四环制药有限公司 一种阿奇霉素药用组合物及其制备方法和其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RU2066324C1 (ru) * 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
TW271400B (pt) * 1992-07-30 1996-03-01 Pfizer
US5795871A (en) * 1994-04-26 1998-08-18 Nobuhiro Narita Pharmaceutical composition for treatment of non-small cell lung cancer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
KR100232297B1 (ko) * 1994-05-06 1999-12-01 디. 제이. 우드 아지트로마이신의 제어된 방출 투여형 제제
IL119866A (en) 1996-12-19 1999-12-31 Unipharm Ltd Antibiotic tablet
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
DK1011689T3 (da) * 1997-09-10 2007-05-21 Merial Ltd Anvendelse af 9a-azalider som veterinære antimikrobielle midler
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
EP1484062A1 (en) * 1998-11-30 2004-12-08 Teva Pharmaceutical Industries Limited Crystalline azithromycin, process for manufacture and pharmaceutical compositions thereof
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
DK1446010T3 (da) * 2001-10-18 2009-06-22 Teva Pharma Stabiliseret azithromycin-sammensætning
EP1455758A1 (en) * 2001-12-21 2004-09-15 Pfizer Products Inc. Directly compressible formulations of azithromycin
WO2003053399A2 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Methods for wet granulating azithromycin
BR0307331A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina

Also Published As

Publication number Publication date
CA2469246A1 (en) 2003-07-03
EP1455758A1 (en) 2004-09-15
NO20043110L (no) 2004-07-20
WO2003053416A1 (en) 2003-07-03
ZA200403486B (en) 2006-05-31
AR037930A1 (es) 2004-12-22
US20060024363A1 (en) 2006-02-02
KR20040066175A (ko) 2004-07-23
US20050287209A1 (en) 2005-12-29
PA8562201A1 (es) 2003-07-28
JP2005513099A (ja) 2005-05-12
TW200301138A (en) 2003-07-01
US20060024364A1 (en) 2006-02-02
US7070811B2 (en) 2006-07-04
RU2277914C2 (ru) 2006-06-20
US20030165563A1 (en) 2003-09-04
MXPA04005105A (es) 2004-08-19
CN1668282A (zh) 2005-09-14
PL371259A1 (en) 2005-06-13
IL161996A0 (en) 2005-11-20
AU2002348884A1 (en) 2003-07-09
RU2004118709A (ru) 2005-04-20
KR100632339B1 (ko) 2006-10-12
NZ532707A (en) 2006-07-28
PE20030591A1 (es) 2003-07-12

Similar Documents

Publication Publication Date Title
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
TW200633730A (en) Oral disintegrating dosage forms
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
BR0213288A (pt) Etilcelulose altamente compressìvel para formação de comprimidos
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
HK1077208A1 (en) Topical composition containing at least one vitminD or one vitamin D analogue and at least one cort icosteroid
TR200002207T1 (tr) Slekoksib bileşikleri.
ES2187822T3 (es) Comprimidos de disgregacion rapida.
BR0015188A (pt) Composições farmacêuticas
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
HK1076605A1 (en) Formulations
RS52651B (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENS AND / OR ESTROGENS AND 5-METHYL- (6S) -TETRAHYDROPHOLATE
BR0211972A (pt) Composição oftálmica
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
GB0012362D0 (en) Chemical compounds
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
HUP0300709A2 (hu) Pemetrexedet monotioglikollal, L-ciszteinnel vagy tioglikolsavval együtt tartalmazó gyógyászati készítmény
BR0111868A (pt) Composições farmacêuticas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/20; A61K 31/7052; A61P 31/00

Ipc: A61K 9/20 (2011.01), A61K 31/7052 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.